¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Small inhibitory RNA"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • gastric inhibitory polypeptide
    À§¾ïÁ¦Æú¸®ÆéƼµå
  • hypothalamic inhibitory hormone
    ½Ã»óÇϺξïÁ¦È£¸£¸ó
  • inhibitory action
    ¾ïÁ¦ÀÛ¿ë, ÀúÁöÀÛ¿ë
  • inhibitory enzyme
    ¾ïÁ¦È¿¼Ò
  • inhibitory hormone
    ¾ïÁ¦È£¸£¸ó
  • inhibitory interneuron
    ¾ïÁ¦»çÀ̽Ű漼Æ÷, ¾ïÁ¦°³Àç´º·±
  • inhibitory postsynaptic potential
    ¾ïÁ¦½Ã³ÀÀÌÈÄÀüÀ§, ¾ïÁ¦¿¬Á¢ÀÌÈÄÀüÀ§
  • inhibitory synapse
    ¾ïÁ¦½Ã³À½º, ¾ïÁ¦¿¬Á¢
  • inhibitory transmitter
    ¾ïÁ¦Àü´Þ¹°Áú
  • leukocyte inhibitory factor
    ¹éÇ÷±¸¾ïÁ¦ÀÎÀÚ
  • luteotrophic hormone inhibitory factor
    Ȳ(»ö)üÀÚ±ØÈ£¸£¸ó¾ïÁ¦ÀÎÀÚ
  • lymphocyte inhibitory factor
    ¸²ÇÁ±¸¾ïÁ¦ÀÎÀÚ
  • minimal inhibitory concentration
    ÃÖÀú¾ïÁ¦³óµµ
  • macrophage migration inhibitory factor
    Å«Æ÷½Ä¼¼Æ÷À̵¿ÀúÁöÀÎÀÚ, ´ë½Ä¼¼Æ÷À̵¿ÀúÁöÀÎÀÚ
  • prolactin inhibitory factor
    ÇÁ·Î¶ôƾºÐºñ¾ïÁ¦ÀÎÀÚ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • inhibitory action
    ¾ïÁ¦ÀÛ¿ë, ÀúÁöÀÛ¿ë
  • reticular inhibitory area
    ±×¹°Ã¼¾ïÁ¦ºÎÀ§
  • central inhibitory state
    ÁßÃß¾ïÁ¦»óÅÂ
  • minimal inhibitory concentration
    ÃÖÀú¾ïÁ¦³óµµ, ÃÖÀúÀúÁö³óµµ
  • inhibitory effect
    ¾ïÁ¦È¿°ú
  • inhibitory enzyme
    ¾ïÁ¦È¿¼Ò
  • leukocyte inhibitory factor
    ¹éÇ÷±¸¾ïÁ¦ÀÎÀÚ
  • luteotrophic hormone inhibitory factor
    ȲüÀÚ±ØÈ£¸£¸ó¾ïÁ¦ÀÎÀÚ
  • lymphocyte inhibitory factor
    ¸²ÇÁ±¸¾ïÁ¦ÀÎÀÚ
  • macrophage migration inhibitory factor
    Å«Æ÷½Ä¼¼Æ÷À̵¿ÀúÁöÀÎÀÚ
  • peripheral inhibitory field
    ¸»ÃʾïÁ¦¿µ¿ª
  • prolactin inhibitory factor
    ÇÁ·Î¶ôƾºÐºñ¾ïÁ¦ÀÎÀÚ
  • virus inhibitory factor
    ¹ÙÀÌ·¯½º¾ïÁ¦ÀÎÀÚ
  • hypothalamic inhibitory hormone
    ½Ã»óÇϺξïÁ¦È£¸£¸ó
  • inhibitory hormone
    ¾ïÁ¦È£¸£¸ó
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • RNA splicing
    RNA ½ºÇöóÀ̽Ì, RNA Àç´Ü, RNA Â¥±é±â
  • RNA virus
    RNA¹ÙÀÌ·¯½º.
  • RNA virus
    RNA ¹ÙÀÌ·¯½º
  • RNA, ribosomal
    ¸®º¸¼Ø RNA, rRNA
  • RNA, transfer
    Àü´ÞRNA, tRNA
  • RNA,, messenger
    Àü·É RNA, mRNA
  • RNA-dependent DNA polymerase
    RNA-ÀÇÁ¸ DNA ÁßÇÕÈ¿¼Ò
  • RNA=£¾ribonucleic acid
    ¸®º¸ÇÙ»ê.
  • hybridization, DNA-RNA
    DNA-RNA ¦Áö¿ì±â, DNA-RNA ºÎÇÕÈ­(~ݬùêûù)
  • immunogen RNA
    ¸é¿ª¿ø¼º RNA.
  • inhibitory action
    ÀúÁöÀÛ¿ë(îÁò­íÂéÄ).
  • inhibitory autacoid
    ¾ïÁ¦¿À¿ÀŸÄÚÀ̵å.
  • inhibitory concentration, minimum (MIC)
    ¾ïÁ¦ÃÖ¼Ò³óµµ
  • inhibitory effect
    ¾ïÁ¦È¿°ú(åäð¤ Íý).
  • inhibitory effect
    ¾ïÁ¦È¿°ú.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • ribonucleic acid =RNA
    ¸®º¸ÇÙ»ê (¡­ú·ß«).
  • ribosomal RNA
    ¸®º¸¼Ø¸®º¸ÇÙ»ê(¡­ú·ß«).
  • rna oncogenic virus
    RNA(¸®º¸ÇÙ»ê)¹ß¾Ï¼º ¹ÙÀÌ·¯½º(Û¡äßàõ¡­)
  • subgenomic RNA
    ¾ÆÁö³ð RNA
  • subgenomic m-RNA
    ¾ÆÁö³ð mRNA
  • transfer RNA
    ÀüÀÌ RNA
  • central inhibitory state
    ÁßÃß¾ïÁ¦»óÅÂ.
  • central inhibitory state
    ÁßÃß¼º ¾ïÁ¦»óÅÂ
  • inhibitory action
    ÀúÁöÀÛ¿ë(îÁò­íÂéÄ).
  • inhibitory autacoid
    ¾ïÁ¦¿À¿ÀŸÄÚÀ̵å.
  • inhibitory concentration, minimum (MIC)
    ¾ïÁ¦ÃÖ¼Ò³óµµ
  • inhibitory effect
    ¾ïÁ¦È¿°ú.
  • inhibitory effect
    ¾ïÁ¦È¿°ú(åäð¤ Íý).
  • inhibitory enzyme
    ÀúÇØÈ¿¼Ò.
  • inhibitory hormone
    ¾ïÁ¦(åäð¤)È£¸£¸ó.
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • adapter RNA
    ¾Æ´äÅÍ RNA
  • adaptor RNA
    ¾Æ´äÅÍ RNA
  • amino acid accepting RNA
    ¾Æ¹Ì³ë»ê(ß«) ¼ö³³(áôÒ¡)RNA
  • chromosomal RNA
    ¿°»öü(æøßäô÷) RNA
  • complementary RNA
    »óº¸¼º(ßÓÜÍàõ) RNA
  • complex RNA
    º¹ÇÕ(ÜÜùê) RNA
  • DNA-dependent RNA polymerase
    DNAÀÇÁ¸ RNA Æú¸®¸Ó·¹À̽º
  • DNA-like RNA
    DNAÀ¯»ç(×¾ÞÄ) RNA
  • DNA-RNA hybrid
    DNA-RNA Æ¢±â
  • DNA-RNA virus
    "DNA-RNA ¹ÙÀÌ·¯½º, (ÔÒ) retrovirus"
  • early RNA
    Á¶±â(ðÄÑ¢) RNA
  • giant messenger-like RNA
    °Å´ë(ËÝÓÞ) À¯»çÀü·É(×¾ÞÄîîÖµ) RNA
  • giant RNA
    °Å´ë(ËÝÓÞ) RNA
  • heterogeneous nuclear RNA
    ÀÌÁú(ì¶òõ) ÇÙ(ú·)RNA
  • immediate early RNA
    ÃÖÁ¶±â(õÌðÄÑ¢) RNA
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
U-RNA uridylic acid ribonucleic acid
SAS sarcoma amplified sequence; self-rating anxiety scale; short arm splint; Sklar Aphasia Scale; sleep ...
SCC self-care center; sequential combination chemotherapy; services for crippled children; short-course ...
GIP   1) Giant cell Interstitial Pneumonia
  2) Gastric Inhibitory (Poly)Peptide
IPSP Inhibitory Post-Synaptic Potential; ¾ïÁ¦¼º ½Ã³À½ºÈÄ ÀüÀ§
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
RDRP RNA dependent RNA polymerase
sat RNA satellite RNA
n-RNA nuclear RNA
EBER EBV encoded small RNA
EBER-1 EBV encoded small RNA-1
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • small vein
    ¼ÒÁ¤¸Æ, ¼¼Á¤¸Æ
  • central inhibitory connection
    ÁßÃß ¾ïÁ¦ ¿¬°á
  • descending inhibitory system
    ÇÏÇà ¾ïÁ¦°è
  • effector-inhibitory factor
    È¿°ú±â ¾ïÁ¦ ÀÎÀÚ
  • inhibitory
    ¾ïÁ¦¼º
    °úÁ¤À» ¾ïÁ¦ ¶Ç´Â ÀúÁöÇÏ´Â. ºÎºÐÀûÀ¸·Î ¶Ç´Â ¿ÏÀüÈ÷ Á¤Ã¼, Á¤Áö½ÃŰ´Â.
  • inhibitory afferent input
    ¾ïÁ¦¼º ±¸½É¼º ÀÔ·Â
  • inhibitory contribution
    ¾ïÁ¦¼º ºÐÆ÷
  • inhibitory hormone
    ¾ïÁ¦ È£¸£¸ó
    Ç¥Àû ±â°ü¿¡ ´ëÇÏ¿© ¾ïÁ¦ÀûÀ¸·Î ÀÛ¿ëÇϴ ȣ¸£¸ó.
  • inhibitory input
    ¿ªÁ¦¼º ÀÔ·Â
  • inhibitory interneuron
    ¾ïÁ¦ °³Àç ´º¿ì·±
  • inhibitory output cell
    ¾ïÁ¦ Ãâ·Â ¼¼Æ÷
  • inhibitory postsynaptic potential
    ¾ïÁ¦¼º ½Ã³³½ºÈÄ Àü¾Ð
    ¾ïÁ¦¼º ±¸½É·Î¿¡ ÀÏÁ¦È÷ Ãæµ¿ÀÌ °¡ÇØÁú ¶§ ½Ã³À½º ÈÄ ´º·Ð¿¡ ¹ßÇàÇÏ´Â ¸·ÀüÀ§ÀÇ Àϰú¼º °úºÐ±ØÀ̸ç, ÀÌ ¶§¹®¿¡ ½Å°æ ´ÜÀ§ÀÇ ¹ÝÀÀ¼ºÀÌ °¨¾àµÈ´Ù.
  • inhibitory substantia gelatinosa cell
    ¾ïÁ¦¼º ±³¾çÁú ¼¼Æ÷
  • inhibitory synapse
    ¾ïÁ¦¼º ½Ã³³½º
  • light touch inhibitory
    ºÒºû ÀÚ±Ø ¾ïÁ¦
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
inhibitory postsynaptic potential The change in potential produced in the membrane of the next neuron when an impulse which has an inhibitory influence arrives at the synapse; it is a local change in the direction of hyperpolarization; the frequency of discharge of a given neuron is determined by the extent to which impulses that lead to excitatory postsynaptic potential's predominate over those that cause inhibitory postsynaptic potential's.
(05 Mar 2000)
inhibitory synapse A synapse in which an action potential in the presynaptic cell reduces the probability of an action potential occurring in the postsynaptic cell. The most common inhibitory neurotransmitter is GABA, this opens channels in the postsynaptic cell which tend to stabilise its resting potential, thus rendering it less likely to fire.
See: excitatory synapse, presynaptic inhibition, postsynaptic inhibition.
(18 Nov 1997)
Leukaemia inhibitory factor <growth factor> Polypeptide growth factor or cytokine with wide range of activities. Regulates growth and differentiation of primordial germ cells and embryonic stem cells but has effects on peripheral neurons, osteoblasts, adipocytes and various cells of the myeloid lineage. Given to adult animals induces weight loss, behavioural disorders and bone abnormalities. Many of the effects of LIF in vitro can be mimicked by IL-6, oncostatin M and ciliary neurotrophic factor, all of which interact indirectly with gp130, a shared tranducer subunit.
(18 Nov 1997)
leukocyte migration-inhibitory factors Protein factor(s) released by sensitised lymphocytes (and possibly other cells) that inhibit the movement of leukocytes, especially polymorphonuclear cells, away from their site of release. Assays for these factors are used as tests for cellular immunity. Two of the common assays are the leukocyte migration capillary tube technique (lmct) and the leukocyte migration agarose technique (lmat).
(12 Dec 1998)
bilaterally small, smooth kidneys <radiology> Generalised atherosclerosis, nephrosclerosis - benign and malignant, atheroembolic renal disease, chronic glomerulonephritis, papillary necrosis, hereditary diseases, hereditary chronic nephritis (Alport's syndrome), medullary cystic disease, amyloidosis (late), arterial hypotension Cf: other urographic patterns
(12 Dec 1998)
carcinoma, non-small-cell lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. They are dealt with collectively because of the shared properties of poor response to conventional chemotherapy and the potential for cure with surgical resection in a fraction of patients.
(12 Dec 1998)
carcinoma, small cell An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterised by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. There are admixtures of small cell lung carcinoma with other types of lung cancer. Small cell carcinomas are distinguished by their distinctive biological features, response to chemotherapy and radiotherapy, and by their nearly universal tendency to develop overt or subclinical metastases, which frequently eliminates surgery in most patients.
(12 Dec 1998)
generalised small bowel disease <radiology> Hypoproteinaemia, sprue, Whipple
(12 Dec 1998)
mesenteric portion of small intestine The freely movable portion of the small intestine supplied with a mesentery, comprising the jejunum and ileum.
Synonym: mesenteric portion of small intestine.
(05 Mar 2000)
ribonucleoproteins, small nuclear Highly conserved nuclear RNA-protein complexes that function in RNA processing in the nucleus, including pre-mRNA splicing and pre-mRNA 3'-end processing in the nucleoplasm. The u3 snrnp is localised in the nucleolus, where it aligns into base pairs with the 28s rrna precursor in a still unidentified region and functions in pre-rrna processing. The u7 snrnp aligns into base pairs with a conserved sequence in the 3'-end of histone pre-mRNA and is an essential cofactor for the cleavage that creates the mature nonadenylated 3'-end.
(12 Dec 1998)
ribonucleoproteins, small, u1 A nuclear RNA-protein complex that plays a role in RNA processing. In the nucleoplasm, the u1 snrnp along with other small ribonucleoproteins (u2, u4-u6, and u5) assemble into spliceosomes that remove introns from pre-mRNA by splicing. The u1 snrnp base pairs with conserved sequence motifs at the 5'-splice site and recognises both the 5'- and 3'-splice sites and may have a fundamental role in aligning the two sites for the splicing reaction.
(12 Dec 1998)
ribonucleoproteins, small, u2 A nuclear RNA-protein complex that plays a role in RNA processing. In the nucleoplasm, the u2 snrnp along with other small ribonucleoproteins (u1, u4-u6, and u5) assemble into spliceosomes that remove introns from pre-mRNA by splicing. The u2 snrnp base pairs with conserved sequence motifs at the branch point, which associates with a heat- and rnaase-sensitive factor in an early step of splicing.
(12 Dec 1998)
ribonucleoproteins, small, u4-u6 A nuclear RNA-protein complex that plays a role in RNA processing. In the nucleoplasm, the u4-u6 snrnp along with the u5 snrnp preassemble into a single 25s particle that binds to the u1 and u2 snrnps and the substrate to form mature spliceosomes. There is also evidence for the existence of individual u4 or u6 snrnps in addition to their organization as a u4-u6 snrnp.
(12 Dec 1998)
ribonucleoproteins, small, u5 A nuclear RNA-protein complex that plays a role in RNA processing. In the nucleoplasm, the u5 snrnp along with u4-u6 snrnp preassemble into a single 25s particle that binds to the u1 and u2 snrnps and the substrate to form mature spliceosomes.
(12 Dec 1998)
mucosa of small intestine The mucous coat of the small intestine.
Synonym: tunica mucosa intestini tenuis.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • small fry
    ¾î¸°¾Öµé;ÀÛÀº µ¿¹°;½Ã½ÃÇÑ Ä£±¸µé;ÀÛÀº µ¿¹°;µ¿¹°ÀÇ »õ³¢;ÀÛÀº ¹°°í±â
  • small holder
    ¼Ò ÀÚÀÛ³ó
  • small holding
    ¼ÒÀÚÀÛ ³óÁö
  • small hours
    ÇѹãÁß(1,2,3½Ã°æ)
  • small potatoes
    ½Ã½ÃÇÑ °Í
  • small rain
    ºÎ½½ºñ;À̽½ºñ !
  • small talk
    ÇÑ´ã;¼¼»ó À̾߱â
  • small time
    (ÇÏ·ç¿¡ ¸î¹ø¾¿ »ó¿¬ÇÏ´Â)½Î±¸·Á ¿¬¿¹(¿¬±Ø)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á